Clinical trials: Staphylococcus Aureus Infections
Gram-positive Bacterial Infections, Staphylococcal Infections
Oral Antibiotic Treatment at Home Instead of Intravenous Treatment in Hospital for Resistant Gram Positive Infections
The main purpose of this study is to find out whether changing the hospital policy to allow switch from glycopeptide antibiotics (given by intravenous drip), to an equally effective oral antibiotic (linezolid) will enable…
- Trial name
- NCT00501150
- Testing
- linezolid
- Where
- United Kingdom
- Volunteers
- 211 people
- Sponsor
- Imperial College London
Soft Tissue Infections, Necrotizing Fasciitis
Systems Medicine to Study Necrotizing Soft Tissue Infections (NSTIs).
This proposal focuses on highly lethal destructive tissue infections, i.e. necrotizing fasciitis and other necrotizing soft tissue infections (NSTIs), which are associated with high morbidity and mortality.
- Conditions
- Soft Tissue Infections, Necrotizing Fasciitis, Necrotizing Soft Tissue Infections
- Trial name
- INFECT (NCT01790698)
- Where
- 5 sites in Denmark, Norway and 1 more
- Volunteers
- 409 people
- Sponsor
- Karolinska Institutet
Pneumonia, Bacterial
Rapid De-escalation of Anti-MRSA Therapy Guided by S. Aureus Nares Screening in Case of Pneumonia
The current IDSA/ATS guidelines recommend Linezolid and Vancomycin for MRSA coverage in hospitalized patients with pneumonia, which is common clinical practice in Italy.
- Trial name
- SNAP (NCT06238297)
- Testing
- MRSA nasal swab based de-escalation
- Where
- Italy
- Volunteers
- 76 people
- Sponsor
- University of Bari Aldo Moro
Cystic Fibrosis, Methicillin-resistant Staphylococcus Aureus
Early Methicillin-resistant Staphylococcus Aureus (MRSA) Therapy in Cystic Fibrosis (CF)
Purpose: There has been a recent, rapid increase in prevalence of Methicillin-resistant Staphylococcus aureus (MRSA) among patients with Cystic Fibrosis (22% across US CF centers in 2009).
- Trial name
- STAR-Too (NCT01349192)
- Testing
- Rifampin, Trimethoprim/Sulfamethoxazole, Minocycline
- Where
- 13 sites in United States
- Volunteers
- 47 people
- Sponsor
- University of North Carolina, Chapel Hill
S. Aureus Transmission, Surgical Site Infection
Reducing Perioperative S. Aureus Transmission Via OR PathTrac
Healthcare-associated infections (HAIs) occur frequently and are associated with patient harm. It is important that healthcare facilities take the necessary steps to prevent the spread of resistant bacteria.
- Trial name
- NCT04657185
- Testing
- OR PathTrac Feedback Optimization
- Where
- United States
- Volunteers
- 804 people
- Sponsor
- Georgetown University
Abscess
Emergency Bedside Ultrasound for Pediatric Soft Tissue Infections
The purpose of this study is to determine if soft tissue infections in pediatric patients can be more accurately diagnosed (i.e.
- Trial name
- NCT00595881
- Testing
- Bedside emergency ultrasound
- Where
- United States
- Volunteers
- 420 people, healthy volunteers welcome
- Sponsor
- Children's Hospital of Philadelphia
Staphylococcal Vaccine
Safety and Efficacy of SA4Ag Vaccine in Adults Having Elective Open Posterior Spinal Fusion Procedures With Multilevel Instrumentation
The purposes of the clinical trial are to determine whether the SA4Ag vaccine can prevent postoperative Staphylococcus aureus infections in patients who are undergoing elective spinal fusion surgery, and to evaluate the safety of…
- Trial name
- STRIVE (NCT02388165)
- Testing
- Staphylococcus aureus 4-Antigen (SA4Ag) Vaccine
- Where
- 301 sites in United States, Austria and 9 more
- Volunteers
- 3,450 people
- Sponsor
- Pfizer
Bacteremia, Staphylococcal Infection
MicroPhage S. Aureus / MSSA / MRSA Blood Culture Beta Trial
In-vitro identification of S. aureus, methicillin-sensitive S. aureus (MSSA), and methicillin-resistant S. aureus (MRSA) from positive blood cultures by MicroPhage's bacteriophage-based diagnostic platform.
- Conditions
- Bacteremia, Staphylococcal Infection, Sepsis, Infection
- Trial name
- NCT00814151
- Testing
- MicroPhage S. aureus / MSSA / MRSA Blood Culture Test (prototype)
- Where
- 3 sites in United States
- Volunteers
- 712 people
- Sponsor
- MicroPhage, Inc.
Bacterial Infections
Clinical Impact of Rapid AST Directly From Blood Cultures
Bacteremia is defined as pathogenic bacteria presence in blood as evidenced by positive blood cultures. These bacteremia have significant consequences in terms of morbidity and mortality (ref. 1,2,3).
- Trial name
- MHR-BC (NCT03992703)
- Where
- France
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Fondation Hôpital Saint-Joseph
Bone and Joint Infections
Clinical Evaluation of Daptomycin Bone Penetration
Bone and joint infections are commonly due to Gram-positive bacteria. Treatment of these infections is difficult because of the need of prolonged duration of antimicrobial agents in combination with surgical procedure.
- Trial name
- DAPTO-HUS (NCT01306825)
- Where
- 3 sites in France
- Volunteers
- 15 people
- Sponsor
- University Hospital, Strasbourg, France
Methicillin-resistant Staphylococcus Aureus Septicemia
The Most Appropriate Parameter Correlates With Clinical Effectiveness of Vancomycin: Trough Drug Concentration or Area Under Curve (AUC)/Minimum Inhibitory Concentration (MIC)?
The purpose of this study is to evaluate which is the most appropriate parameter correlates with clinical effectiveness of vancomycin: trough drug level or AUC/MIC.
- Trial name
- NCT01995760
- Where
- Taiwan
- Volunteers
- 123 people
- Sponsor
- National Taiwan University Hospital
Staphylococcus Aureus, Surgical Wound Infection
Advanced Understanding of Staphylococcus Aureus Infections in Europe - Surgical Site Infections
ASPIRE-SSI is a prospective, observational, multicentre cohort study among adult surgical patients, which aims to determine the incidence of healthcare-associated S. aureus infections, particularly S.
- Trial name
- ASPIRE-SSI (NCT02935244)
- Where
- 33 sites in Belgium, Czechia and 8 more
- Volunteers
- 5,004 people
- Sponsor
- UMC Utrecht
the Aim of This Study is to Describe Genomic Epidemiology of MSSA in Neonatal ICU
Epidemiology and Genomic Surveillance of Staphylococcus Aureus in ICU Neonatology
Newborns hospitalized in Neonatology are particularly vulnerable to infections, in particular healthcare associated infection (HAI).
- Trial name
- NEOSAUR (NCT06267352)
- Volunteers
- 120 people
- Sponsor
- University Hospital, Caen
MRSA - Methicillin Resistant Staphylococcus Aureus Infection
Vascular Surgical Antibiotic Prophylaxis Study (VSAPS 2)
The current recommended antibiotic, Cefazolin, treatment for vascular surgery, provides coverage only for Methicillin-Sensitive Staphylococcus Aureaus (MSSA), other gram-positive bacteria, and some gram-negative bacteria which…
- Trial name
- NCT01612052
- Testing
- Antibiotic Prophylaxis
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- CAMC Health System
Staphylococcus Aureus, Atopic Dermatitis
Exploratory Study to Evaluate the Application of NLAC Cream in Adults With Atopic Dermatitis
Atopic dermatitis (AD) is the most common chronic inflammatory skin disorder, with a lifetime prevalence of 15-25% in children and 1-3% in adults worldwide.
- Trial name
- NCT05092464
- Testing
- Natural Lactic Acid-enriched Cream
- Volunteers
- 10 people
- Sponsor
- Microbio Co Ltd
Infective Endocarditis
Phase 4 Efficacy and Safety Study of Cubicin® With and Without Combination Therapy in S. Aureus Infective Endocarditis (SAIE)
multicenter, randomized, double blind study to describe the safety and efficacy of daptomycin (6 mg/kg q24h) with and without concomitant initial gentamicin combination therapy in the treatment of SAIE
- Trial name
- NCT00638157
- Testing
- daptomycin, daptomycin and gentamicin
- Where
- 4 sites in United States
- Volunteers
- 24 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Endocarditis
Safety, Efficacy and Pharmacokinetics of CF-301 vs. Placebo in Addition to Antibacterial Therapy for Treatment of S. Aureus Bacteremia
The purpose of this study is to evaluate the safety, tolerability, efficacy and pharmacokinetics (PK) of CF-301 in addition to background standard of care (SOC) antibacterial therapy for the treatment of Staphylococcus aureus (S.
- Trial name
- NCT03163446
- Testing
- CF-301
- Where
- 78 sites in United States, Belgium and 12 more
- Volunteers
- 121 people
- Sponsor
- ContraFect
Bacteremia Due to Staphylococcus Aureus
Vancomycin Versus Daptomycin for the Treatment of Methicillin Resistant Staphylococcus Aureus (MRSA) Bacteremia
The aim of this study is to compare the efficacy of daptomycin treatment versus vancomycin treatment in the treatment of methicillin resistant staphylococcus aureus (MRSA) bloodstream infections (BSI) due to isolates with high…
- Trial name
- NCT01975662
- Testing
- Daptomycin, Vancomycin
- Where
- Singapore
- Volunteers
- 14 people
- Sponsor
- Singapore General Hospital
Infective Endocarditis, Necrotizing Fasciitis
Coagulation and Fibrinolysis as Virulence Factors for Invasive Staphylococcus Aureus and Streptococcus Infections
the aim of this study is to investigate the role of staphylokinase, streptokinase and MMP activation in invasive staphylococcal and streptococcal infections.
- Trial name
- NCT01731483
- Where
- Belgium
- Volunteers
- 89 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Staphylococcal Infection
Study to Assess Eradication of Nasal Carriage of Staphylococcus Aureus (SA) With Mupirocin (Bactroban 2% Nasal Ointment)
This study will assess the nasal eradication of SA in healthy subjects following treatment with mupirocin 2% (Bactroban 2% Nasal Ointment) twice daily for 5 days, by means of a broth enriched culture microbial assay.
- Trial name
- NCT02284555
- Testing
- Mupirocin
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Destiny Pharma Plc